Xiuning Le/X
May 1, 2025, 07:04
Xiuning Le Highlights ctDNA EGFR Mutation Insights from RAMOSE Trial at AACR25
Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on X:
“Dr. Simon Heek presented ‘Association of baseline ctDNA EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinibversus osimertinibin EGFR+ Lung Cancer.’
Baseline assessment of EGFR mutations from ctDNA is feasible with short turn-around time
ctDNA EGFR VAF >0.5% is associated with significantly shorter PFS
Detectable EGFR mutations from ctDNA at baseline was associated with numerically shorter PFS
No deaths occurred in patients without detectable EGFRmutations in ctDNA
We will report on-treatment ctDNA association and radiomics translational work in future conferences”
More posts featuring AACR25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 1, 2025, 16:20
May 1, 2025, 15:20
May 1, 2025, 14:51
May 1, 2025, 14:30
May 1, 2025, 14:00
May 1, 2025, 13:26